• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Venture fund Foresite Capital raises largest-ever $668m fund

May 4, 2018 By Brad Perriello

Foresite CapitalLife sciences venture firm Foresite Capital said today that it raised a record $668 million for its fourth fund, bringing its assets-under-management tally to $2 billion.

San Francisco-based Foresite was founded in 2011 by former Theravance co-founder & CEO Dr. Jim Tananbaum. Investors in its fourth fund include “a significant representation of existing investors, including university endowments, pension funds, insurance companies and foundations” and some new investors, the company said today.

“At Foresite Capital we’ve brought together a unique value proposition for our portfolio companies. We not only provide capital from seed to public stage, but also a multidisciplinary team of scientists, clinicians, analysts and engineers who collaborate to seek the best data-driven decisions. The ability to ingest and derive meaning from massive amounts of complex information is a critical success factor in healthcare investing,” Tananbaum said in prepared remarks. “We’re pleased by the confidence and enthusiasm our Fund IV investors have demonstrated in the Foresite Capital team, as well as the progress made by our rapidly developing portfolio.”

“We are focused on meaningfully improving patient health and well-being. We are privileged to work with creative healthcare and life sciences entrepreneurs, whose efforts continue to advance our understanding of disease and provide innovative approaches to address patient needs,” added managing director Dr. Dorothy Margolskee.

Foresite has a stake in several big-name life science outfits, including Intarcia Therapeutics, Aerie Pharmaceuticals and 10x Genomics.

Filed Under: Featured, Funding Roundup, Wall Street Beat Tagged With: Foresite Capital

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS